Delving into the Latest Updates on ANHUI NEW STAR PHARMACEUTICAL DEVELOPMENT Co Ltd with Synapse

Overview

Tags

Nervous System Diseases

Other Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

NET x μ opioid receptor	1

本试验旨在空腹/高脂餐后给药条件下，以药代动力学参数为终点指标，考察安徽新星药物开发有限责任公司生产的盐酸他喷他多片与DEPOMED INC生产的盐酸他喷他多片（NUCYNTA®，规格：75mg）人体药代动力学特征，对两制剂的生物等效性进行评价。

[Translation]

The purpose of this study was to investigate the pharmacokinetic characteristics of tapentadol hydrochloride tablets produced by Anhui Xinxing Pharmaceutical Development Co., Ltd. and tapentadol hydrochloride tablets (NUCYNTA®, specification: 75 mg) produced by DEPOMED INC under fasting/high-fat meal administration conditions, using pharmacokinetic parameters as endpoint indicators, and to evaluate the bioequivalence of the two preparations.

Start Date21 Sep 2019

Sponsor / Collaborator

ANHUI NEW STAR PHARMACEUTICAL DEVELOPMENT Co Ltd

CTR20170985

/ CompletedPhase 1

开放、随机、单次给药、三周期部分重复交叉试验设计，评价空腹状态下米诺膦酸片健康人体生物等效性试验

[Translation] An open, randomized, single-dose, three-period partially repeated crossover study designed to evaluate the bioequivalence of minodronic acid tablets in healthy volunteers under fasting conditions

本试验采用开放、随机、单次给药、三周期部分重复交叉试验设计，以原研药Astellas Pharma Inc.公司生产的米诺膦酸片（商品名：Bonoteo®）为参比制剂，评价空腹状态下江苏天士力帝益药业有限公司生产的受试制剂米诺膦酸片在中国健康志愿者体内药代动力学和生物等效性。为注册提供临床依据。

[Translation]

This trial adopts an open, randomized, single-dose, three-period partially repeated crossover design, using minodronic acid tablets (trade name: Bonoteo®) produced by the original drug Astellas Pharma Inc. as the reference preparation to evaluate the pharmacokinetics and bioequivalence of the test preparation minodronic acid tablets produced by Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. in healthy Chinese volunteers under fasting conditions, providing clinical basis for registration.

Start Date14 Aug 2017

Sponsor / Collaborator

ANHUI NEW STAR PHARMACEUTICAL DEVELOPMENT Co Ltd

100 Clinical Results associated with ANHUI NEW STAR PHARMACEUTICAL DEVELOPMENT Co Ltd

Login to view more data

0 Patents (Medical) associated with ANHUI NEW STAR PHARMACEUTICAL DEVELOPMENT Co Ltd

Login to view more data

5

Literatures (Medical) associated with ANHUI NEW STAR PHARMACEUTICAL DEVELOPMENT Co Ltd

01 Mar 2019·FitoterapiaQ3 · MEDICINE

Gambogenic acid triggers apoptosis in human nasopharyngeal carcinoma CNE-2Z cells by activating volume-sensitive outwardly rectifying chloride channel

Q3 · MEDICINE

Article

Author: Liang, Mengru ; Su, Jingjing ; Jiang, Genling ; Hou, Mei ; Cheng, Hui ; Xu, Ting ; Li, Qinglin

Gambogenic acid (GNA) is one of the main components of Gamboge, and its anti-cancer effects have been well confirmed by previous researches. Nasopharyngeal carcinoma (NPC) has not been thoroughly studied, and the pathogenesis of NPC is unclear. Scientists have neither discovered effective therapies nor achieved a desirable prognosis. Some studies have found that the regulation of intra- and extracellular ion channels hinges directly on cell apoptosis, and treatment with GNA brings changes to the volume-sensitive outwardly rectifying chloride (VSOR Cl^-) current of CNE-2Z cells recorded by the patch clamp method. Nevertheless, rarely have any researchers probed into the relevance between this variation and the anti-tumor mechanism of GNA. This paper is suggested that 2.0 μmol/L GNA activates VSOR Cl^- currents on CNE-2Z cell membranes and that the activation of VSOR Cl^- currents by GNA in CNE-2Z cells is blocked by the chloride channel blockers DIDS (400 μmol/L) and DCPIB (20 μmol/L). MQAE experiment further proves that GNA leads to the opening of chloride ion channel, which in turn results in the efflux of VSOR Cl^- current; GNA induces the downregulation of GRP78 and the upregulation of ATF4 and CHOP proteins. These effects are correlated with endoplasmic reticulum (ER) stress. GNA can activate VSOR Cl^- channels, leading to ER stress, inducing apoptosis and inhibiting proliferation in CNE-2Z cells.

Anhui Huagong

Study on the synthesis of 3-amino-4-methylacetophenone

Author: Zhao, Yonghai ; Xu, Ziao ; Niu, Lin

After studying the synthesis method of 3-amino-4-methylacetophenone, the target product 3-amino-4-methylacetophenone from 4-Me acetophenone as starting material, via nitrating was obtained.The total yield was 80%.The process is so simple that it is suitable for industrial production

Anhui Yiyao

Pharmacokinetics and bioavailability of fenofibrate sustained release tablets in healthy volunteers

Author: Zhao, Ya-nan ; Zhou, Li-xiang ; Li, Xiao-xiang

To study the pharmacokinetics and bioavailability of fenofibrate sustained release tablets in healthy volunteers.Twenty healthy male volunteers were enrolled in a randomized open-label, two-crossover study given a single dose of 0.25 g fenofibrate sustained release tablets and fenofibrate sustained release capsules.24 Healthy male volunteers were enrolled in a randomized open-label, two-crossover study given multi-dose of 0.25 g fenofibrate sustained release tablets and fenofibrate sustained release capsules for 6 days.The concentrations of fenofibric acid in plasma were determined by HPLC method.Pharmacokinetic parameters were comparable.Average bioequivalence was determined by DAS 2.0 program.The main pharmacokinetic parameters of fenofibrate sustained release tablets and fenofibrate sustained release capsules were as follows, single-dose: t_1/2 (5.25 ± 1.27) and (4.93 ± 0.71) h, C_max (8.58 ± 2.77) and (9.75 ± 3.44) mg/L^-1, and AUC_0-96 (188.34 ± 65.66) and (194.02 ± 56.58) mg/h^-1/L^-1, and multi-doses: t_max (5.06 ± 0.92) and (5.04 ± 0.93) h, C_av (7.25 ± 2.32) and (8.03 ± 3.27) mg/L^-1, and AUC_ss (174.06 ± 55.67) and (192.66 ± 78.53) mg/h^-1/L^-1.The pharmacokinetic parameters were similar after administration of fenofibrate sustained release tablets and fenofibrate sustained release capsules.The two kinds of fenofibrate are of bioequivalence.

100 Deals associated with ANHUI NEW STAR PHARMACEUTICAL DEVELOPMENT Co Ltd

Login to view more data

100 Translational Medicine associated with ANHUI NEW STAR PHARMACEUTICAL DEVELOPMENT Co Ltd

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Jan 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

2

Login to view more data